Skip to main content

Table 2 Trial and Baseline Patient Characteristics, and Interventions of RCTs in Pericarditis, Post-Pericardiotomy Syndrome and Post-RF Ablation for Arrythmia

From: Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials

 

Acute Pericarditis

Acute Pericarditis

First Re-current Pericarditis

First Re-current Pericarditis

Multiply Recurrent Pericarditis

Post Pericardiotomy Syndrome

Post Pericardiotomy Syndrome

Post Pericardiotomy Syndrome

Post Pericardiotomy Syndrome

Post RF Ablation for Recurrent AFib

Colchicine Dose

0.25-0.5 mg bid (lower dose <70 kg or intolerance)

0.5 mg bid (daily ≤70 kg or intolerance)

0.25-0.5 mg bid (lower dose <70 kg or intolerance)

0.25-0.5 mg bid (lower dose <70 kg or intolerance)

0.5 mg bid (daily ≤70 kg or intolerance)

1.5 mg/d starting POD #3

0.5 mg bid (daily <70 kg) starting POD #3 with loading dose

0.5 mg bid (daily <70 kg) starting 48-72 h pre-op

0.5 mg bid

0.5 mg bid

Trial

COPE (Imazio) 2005 [18]

ICAP (Imazio) 2013 [19]

CORE (Imazio) 2005 [20]

CORP (Imazio) 2011 [21]

CORP-2 (Imazio) 2014 [22

Finkelstein 2002 [23]

COPPS (Imazio) 2010 [24]

COPPS-2 (Imazio) 2014 [25]

Sarzaeem 2014 [26]

Deftereos 2012 [27]

N = 120

N = 240

N = 84

N = 120

N = 240

N = 163

N = 360

N = 360

N = 216

N = 230

Trial Characteristics

          

No. Centres

2

5

1

4

4

2

6

11

1

3

Enrolment period

Jan 2002 – Aug 2004

Aug 2005 – Dec 2010

Jan 2001 – Aug 2004

Aug 2005 – Apr 2009

Nov 2005 – Jan 2012

Oct 1997 – Sept 1998

n/r

Mar 2012 – Mar 2014

Jan 2013 –Jul 2013

n/r

Treatment/ Follow Up

3 months/24 months (mean)

3 months/18 months (all)/ 22 months (mean)

6 months/20 months (mean)

6 months/ 18 months (all)/ 23 months (mean)

6 months/18 months (all)/ 20 months (mean)

1 month/3 months

1 month/19 months (mean)

1 month/3 months

7 days/Hosp discharge (mean 7 days)

3 months/15 (median) months

Funding

Public

Public

Public

Public

Public

n/r

Public

Public

n/r

n/r

Patients

N = 120

N = 240

N = 84

N = 120

N = 240

N = 111

N = 360

N = 360

N = 216

N = 206

Mean Age (years)

57

52

54

48

49

64

66

68

60

62

% Male

45 %

60 %

35 %

53 %

50 %

73 %

67 %

69 %

72 %

70 %

BMI

        

26

26

Diabetes

   

3 %

 

27 %

23 %

22 %

37 %

25 %

HTN

   

23 %

 

46 %

68 %

68 %

53 %

41 %

Smoker

   

49 %

 

48 %

13 %

29 %

30 %

35 %

Dyslipidemia

     

42 %

    

Prev MI/UA

   

11 %

7 %

40 %

21 %

  

34 % (CAD)

Prev stroke/TIA

        

2 %

 

PVD

          

CRD

(Excl Cr >2.5 mg/dL/ 221 μM)

(Excl Cr >2.5 mg/dL/ 221 μM)

(Excl Cr >2.5 mg/dL/ 221 μM)

5 % (CrCl <60 mL/min; Excl Cr >2.5 mg/dL/ 221 μM)

(Excl Cr >2.5 mg/dL/ 221 μM)

 

15 % (CrCl <60 mL/min; Excl Cr >2.5 mg/dL/ 221 μM)

7 % (Excl Cr >2.5 mg/dL/ 221 μM)

Excl

Excl eGFR <30 mL/min

Mean LVEF

   

58 %

  

54 %

55 %

47 %

55 %

Previous CABG

   

6 %

4 %

 

6 %

6 %

Excl

 

Medications

          

ASA and/or clopidogrel

 

76 % (ASA)

  

76 % (ASA)

     

Statin

         

37 %

Beta-Blocker

         

36 %

Calcium Channel Blocker

         

41 %

ACE Inhibitor

         

54 % (incl ARB)

Diuretic

          
  1. Abbreviations: ACE angiotensin converting enzyme, ACS acute coronary syndrome, ARB angiotensin receptor blocker, AFib atrial fibrillation, ASA acetylsalicylic acid (aspirin), bid twice daily, BMI body mass index, BMS bare metal stent, CABG coronary artery bypass grafting, CAD coronary artery disease, CHF congestive heart failure, chol cholesterol, Cr serum creatinine concentration, CrCl creatinine clearance, CRD chronic renal disease, DAPT dual anti-platelet therapy, DM diabetes mellitus, dL deciliter, eGFR estimated glomerular filtration rate, excl excluded, h hour, HTN hypertension, kg kilogram (body weight), LVEF left ventricular ejective fraction, mg milligram, μM micromolar, MI myocardial infarction, mL milliliter, N number of patients, no. number, n/r not reported, PCI percutaneous coronary intervention, POD post-operative day, prev previous, PTCA percutaneous coronary angioplasty, PVD peripheral vascular disease, RF radiofrequency, TIA transient ischemic attack, UA unstable angina, yrs years
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us